A universal, low-immunogenic hiPSC platform was developed using non-genetically modified human stem cells with natural HLA-E and HLA-G expressions. This enables safe, scalable, off-the-shelf therapies with broad population coverage. The hiPSCs demonstrate stable immune evasion in large animal models and can differentiate into multiple somatic lineages. Compliant with GTP standards, this platform supports Taiwan’s regenerative medicine innovation.

We established a gene-editing-free–free, immune-tolerant universal hiPSC bank with high safety, low immunogenicity, and scalable production capacity. This GTP-compliant platform overcomes major barriers in allogeneic cell therapy—immune rejection, regulatory hurdles, and batch consistency. Capable of generating diverse therapeutic cell types, it enhances treatment efficacy and offers a standardized, internationally competitive solution to strengthen Taiwan’s regenerative medicine sector.

We developed a gene-editing–free, immune-tolerant universal hiPSC bank with robust safety, low immunogenicity, and scalable production capacity. This platform addresses key barriers in allogeneic cell therapy—immune rejection, regulatory complexity, and manufacturing inconsistency. GTP-compliant and capable of generating diverse therapeutic cell types, it offers a standardized, high-value solution that enhances clinical outcomes and reinforces Taiwan’s global role in regenerative medicine.